Specialty Pharmacy

Kinesin family member 5A mutations may cause amyotrophic lateral sclerosis.

Women with a prior chlamydia infection could have twice the risk of ovarian cancer.

Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, talks about the potential merits of outcomes-based contracting for drugs that treat rare diseases.

Top news of the day from across the health care landscape.

Ibalizumab-uiyk was the first monoclonal antibody approved to treat HIV.

Pharmacists are crucial members of the health care team but may not get enough credit for their impact.

Genetic sequencing of joint biopsies may identify which patients with rheumatoid arthritis may respond to therapy.

Nintedanib (Ofev) is currently indicated to slow disease progression among patients with idiopathic pulmonary fibrosis.

AbbVie will not seek accelerated approval of Rovalpituzumab Tesirine as a third-line therapy for small cell lung cancer.

Top news of the week from Specialty Pharmacy Times.

None of the participants experienced grade 3 or 4 side effects.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Nilotinib (Tasigna) was previously granted priority review for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Daily doses of sildenafil (Viagra) cut the development of polyps by 50% in mouse models.

Black patients may be eligible for a shorter course of hepatitis C virus treatment.

Biologic drug cannakinumab found to reduce the risk of cardiovascular adverse events among patients with comorbidities.

Individuals who experience high sun exposure during childhood or young adulthood may be less likely to develop multiple sclerosis.

A cellular process could be key to lowering levels of the Huntington disease protein.

Top news of the day from across the health care landscape.

I learned myriad life and professional lessons from my travels.

Tildrakizumab-asmn (Ilumya) approved for the treatment of moderate-to-severe plaque psoriasis.

Matt Gillin, Chief Executive Officer, Relay Network, speaks about how smartphones are crucial to the patient journey.

The addition of atezolizumab (Tecentriq) to chemotherapy may improve outcomes for patients with advanced non-small cell lung cancer.

A PET scan could quickly indicate whether EGRF-targeted therapy would be beneficial to patients with non-small cell lung cancer.

Adding tenofovir disoproxil fumarate to prevention regimens may not effectively stop hepatitis B virus transmission to infants.

Standard colorectal cancer screening guidelines may not accurately assess risks in certain patients.

Top news of the day from across the health care landscape.

The median time to viral suppression decreased from 63 days to 45 days post-rapid entry program.